Stonepine Capital Management, LLC - CUMBERLAND PHARMACEUTICALS I ownership

CUMBERLAND PHARMACEUTICALS I's ticker is CPIX and the CUSIP is 230770109. A total of 27 filers reported holding CUMBERLAND PHARMACEUTICALS I in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Stonepine Capital Management, LLC ownership history of CUMBERLAND PHARMACEUTICALS I
ValueSharesWeighting
Q4 2020$557,000
-70.6%
188,703
-68.0%
0.43%
-78.4%
Q3 2020$1,892,000
-16.0%
589,497
-12.9%
1.97%
-54.9%
Q2 2020$2,253,000
-31.6%
676,592
-25.5%
4.36%
+25.2%
Q1 2020$3,295,000
-28.6%
907,735
+1.3%
3.48%
+8.3%
Q4 2019$4,615,000
-9.5%
896,170
+4.2%
3.22%
-35.0%
Q3 2019$5,102,000
-8.1%
860,449
-1.3%
4.95%
+29.5%
Q2 2019$5,553,000
-20.5%
871,762
-27.5%
3.82%
-4.8%
Q1 2019$6,983,000
-11.8%
1,201,975
-8.5%
4.02%
-42.3%
Q4 2018$7,920,000
+13.8%
1,313,429
+7.8%
6.96%
+71.0%
Q3 2018$6,957,000
-5.7%
1,218,401
+1.3%
4.07%
-9.2%
Q2 2018$7,376,000
-16.5%
1,203,339
-9.0%
4.48%
-5.4%
Q1 2018$8,838,000
-8.1%
1,323,041
+1.2%
4.74%
-17.8%
Q4 2017$9,619,000
+7.1%
1,306,911
+2.7%
5.76%
+8.9%
Q3 2017$8,982,000
+15.7%
1,272,191
+14.7%
5.29%
+26.3%
Q2 2017$7,764,000
+51.2%
1,109,167
+49.9%
4.19%
+44.9%
Q1 2017$5,135,000
+50.7%
739,917
+19.4%
2.89%
+42.6%
Q4 2016$3,407,000
+110.0%
619,538
+91.4%
2.03%
+53.4%
Q3 2016$1,622,000
+179.7%
323,747
+151.4%
1.32%
+122.4%
Q2 2016$580,000128,7980.60%
Other shareholders
CUMBERLAND PHARMACEUTICALS I shareholders Q1 2020
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 896,170$4,615,0003.22%
Ariel Investments 1,010,220$5,203,0000.06%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 183,000$942,0000.01%
Anfield Capital Management, LLC 4,530$23,0000.01%
Financial Gravity Asset Management, Inc. 2,000$10,0000.01%
Oakworth Capital, Inc. 3,052$16,0000.00%
BAILARD, INC. 11,816$61,0000.00%
DIMENSIONAL FUND ADVISORS LP 860,319$4,431,0000.00%
Renaissance Technologies 469,338$2,417,0000.00%
ACADIAN ASSET MANAGEMENT LLC 98,192$506,0000.00%
View complete list of CUMBERLAND PHARMACEUTICALS I shareholders